Tags

Type your tag names separated by a space and hit enter

Development of vaccines against the sexually transmitted infections gonorrhoea, syphilis, Chlamydia, herpes simplex virus, human immunodeficiency virus and Zika virus.
Ther Adv Vaccines Immunother. 2020; 8:2515135520923887.TA

Abstract

The success in preventing hepatitis B virus and human papillomavirus infections by means of vaccination paves the way for the development of other vaccines to prevent sexually transmitted infections (STIs) such as gonorrhoea, syphilis, chlamydia, herpes simplex virus, human immunodeficiency virus and Zika virus. The current status of vaccine development for these infections will be explored in this review. The general principles for success include the need for prevention of latency, persistence and repeat infections. A reduction in transmission of STIs would reduce the global burden of disease. Therapeutic activity of vaccines against STIs would be advantageous over preventative activity alone, and prevention of congenital and neonatal infections would be an added benefit. There would be an added value in the prevention of long-term consequences of STIs. It may be possible to re-purpose 'old' vaccines for new indications. One of the major challenges is the determination of the target populations for STI vaccination.

Authors+Show Affiliations

FEO - Faculty Education Office (Medicine), Imperial College London, Sir Alexander Fleming Building, South Kensington Campus, London, SW7 2AZ, UK.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32647779

Citation

McIntosh, Edwin David G.. "Development of Vaccines Against the Sexually Transmitted Infections Gonorrhoea, Syphilis, Chlamydia, Herpes Simplex Virus, Human Immunodeficiency Virus and Zika Virus." Therapeutic Advances in Vaccines and Immunotherapy, vol. 8, 2020, p. 2515135520923887.
McIntosh EDG. Development of vaccines against the sexually transmitted infections gonorrhoea, syphilis, Chlamydia, herpes simplex virus, human immunodeficiency virus and Zika virus. Ther Adv Vaccines Immunother. 2020;8:2515135520923887.
McIntosh, E. D. G. (2020). Development of vaccines against the sexually transmitted infections gonorrhoea, syphilis, Chlamydia, herpes simplex virus, human immunodeficiency virus and Zika virus. Therapeutic Advances in Vaccines and Immunotherapy, 8, 2515135520923887. https://doi.org/10.1177/2515135520923887
McIntosh EDG. Development of Vaccines Against the Sexually Transmitted Infections Gonorrhoea, Syphilis, Chlamydia, Herpes Simplex Virus, Human Immunodeficiency Virus and Zika Virus. Ther Adv Vaccines Immunother. 2020;8:2515135520923887. PubMed PMID: 32647779.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development of vaccines against the sexually transmitted infections gonorrhoea, syphilis, Chlamydia, herpes simplex virus, human immunodeficiency virus and Zika virus. A1 - McIntosh,Edwin David G, Y1 - 2020/06/27/ PY - 2019/09/16/received PY - 2020/04/07/accepted PY - 2020/7/11/entrez PY - 2020/7/11/pubmed PY - 2020/7/11/medline KW - Zika virus KW - chlamydia KW - gonorrhoea KW - herpes simplex virus KW - human immunodeficiency virus KW - syphilis SP - 2515135520923887 EP - 2515135520923887 JF - Therapeutic advances in vaccines and immunotherapy JO - Ther Adv Vaccines Immunother VL - 8 N2 - The success in preventing hepatitis B virus and human papillomavirus infections by means of vaccination paves the way for the development of other vaccines to prevent sexually transmitted infections (STIs) such as gonorrhoea, syphilis, chlamydia, herpes simplex virus, human immunodeficiency virus and Zika virus. The current status of vaccine development for these infections will be explored in this review. The general principles for success include the need for prevention of latency, persistence and repeat infections. A reduction in transmission of STIs would reduce the global burden of disease. Therapeutic activity of vaccines against STIs would be advantageous over preventative activity alone, and prevention of congenital and neonatal infections would be an added benefit. There would be an added value in the prevention of long-term consequences of STIs. It may be possible to re-purpose 'old' vaccines for new indications. One of the major challenges is the determination of the target populations for STI vaccination. SN - 2515-1355 UR - https://www.unboundmedicine.com/medline/citation/32647779/Development_of_vaccines_against_the_sexually_transmitted_infections_gonorrhoea,_syphilis,_Chlamydia,_herpes_simplex_virus,_human_immunodeficiency_virus_and_Zika_virus DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.